Diferencia entre revisiones de «Pediatric fever of uncertain source»
(→0-28d) |
Sin resumen de edición |
||
| Línea 1: | Línea 1: | ||
==Harbor-UCLA Protocol== | == Harbor-UCLA Protocol == | ||
===0-28dy=== | === 0-28dy === | ||
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1" | |||
|- | |||
| Age Group | |||
| Evaluation | |||
| Treatment | |||
|- | |||
| | |||
0-28d, ≥38C | |||
SBI incidence of ill appearing: 13%–21% | |||
if not ill appearing: <5% | |||
| | |||
CBC, blood Cx | |||
UA, Ucx | |||
CSF cell count, GS, Cx | |||
CXR (only if resp sx) | |||
Stool testing (if diarrhea present) | |||
| | |||
Admit | |||
Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) | |||
|- | |||
| | |||
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol) | |||
<br>SBI incidence of ill appearing: 13%–21% | |||
if not ill appearing: <5% | |||
<br> | |||
| Same as for neonates | |||
| | |||
Discharge if: | |||
1. WBC <15K but >5K and <20% bands | |||
2. UA negative | |||
Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis | |||
|- | |- | ||
| Age Group | | | ||
| Evaluation | 57d-6mo, ≥38 | ||
Non-UTI SBI incidence is estimated to be negligible | |||
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span> | |||
<br> | |||
| | |||
UA and Ucx alone | |||
OR | |||
treat 57-90d using Philadelphia Protocol | |||
| | |||
Discharge if negative | |||
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient | |||
Admit and tx with CTX if fail criteria for d/c | |||
|- | |||
| | |||
57d-6mo, ≥39 (102.2) | |||
SBI incidence is estimated <1%; | |||
non-UTI SBI incidence is estimated to be negligible. | |||
UTI is 3%–8% | |||
| | |||
UA and Ucx alone | |||
OR | |||
UA and Ucx + CBC + blood cx | |||
| | |||
: | |||
Discharge if negative | |||
Treat for UTI as above | |||
If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr | |||
If WBC>20K consider CXR and CSF | |||
|- | |||
| | |||
6–36 mo | |||
Non-UTI SBI incidence is <0.4% | |||
UTI in girls ≤8% | |||
UTI in boys (<12 mo) ≤ 2% | |||
Uncircumcised boys (1–2 y) remains 2% | |||
| | |||
UA and Ucx in: | |||
(girls 6-24mo) | |||
(circ 6-12mo) | |||
(uncirc 6-24mo) | |||
| | |||
Discharge if negative | |||
Treat for UTI as above as outpatient | |||
|- | |||
| >36mo | |||
| No further w/u is routinely necessary | |||
| <br> | |||
|} | |||
=== 28dy-90dy === | |||
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1" | |||
|- | |||
| Age Group | |||
| Evaluation | |||
| Treatment | | Treatment | ||
|- | |- | ||
| | | | ||
0-28d, ≥38C | 0-28d, ≥38C | ||
SBI incidence of ill appearing: 13%–21% | SBI incidence of ill appearing: 13%–21% | ||
if not ill appearing: | if not ill appearing: <5% | ||
| | | | ||
CBC, blood Cx | CBC, blood Cx | ||
UA, Ucx | UA, Ucx | ||
CSF cell count, GS, Cx | CSF cell count, GS, Cx | ||
CXR (only if resp sx) | CXR (only if resp sx) | ||
Stool testing (if diarrhea present) | Stool testing (if diarrhea present) | ||
| | | | ||
Admit | Admit | ||
Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) | Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) | ||
| Línea 40: | Línea 172: | ||
|- | |- | ||
| | | | ||
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol) | 29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol) | ||
<br>SBI incidence of ill appearing: 13%–21% | |||
if not ill appearing: <5% | |||
<br> | |||
| Same as for neonates | |||
| | |||
Discharge if: | |||
1. WBC <15K but >5K and <20% bands | |||
2. UA negative | |||
Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis | |||
|- | |||
| | |||
57d-6mo, ≥38 | |||
Non-UTI SBI incidence is estimated to be negligible | |||
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span> | |||
<br> | |||
| | |||
UA and Ucx alone | |||
OR | |||
treat 57-90d using Philadelphia Protocol | |||
| | |||
Discharge if negative | |||
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient | |||
Admit and tx with CTX if fail criteria for d/c | |||
|- | |||
| | |||
57d-6mo, ≥39 (102.2) | |||
SBI incidence is estimated <1%; | |||
non-UTI SBI incidence is estimated to be negligible. | |||
UTI is 3%–8% | |||
| | |||
UA and Ucx alone | |||
OR | |||
UA and Ucx + CBC + blood cx | |||
| | | | ||
Discharge if | : | ||
Discharge if negative | |||
Treat for UTI as above | |||
If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr | |||
If WBC>20K consider CXR and CSF | |||
2. UA negative | |- | ||
| | |||
6–36 mo | |||
Non-UTI SBI incidence is <0.4% | |||
UTI in girls ≤8% | |||
UTI in boys (<12 mo) ≤ 2% | |||
Uncircumcised boys (1–2 y) remains 2% | |||
| | |||
UA and Ucx in: | |||
(girls 6-24mo) | |||
(circ 6-12mo) | |||
(uncirc 6-24mo) | |||
| | |||
Discharge if negative | |||
Treat for UTI as above as outpatient | |||
|- | |||
| >36mo | |||
| No further w/u is routinely necessary | |||
| <br> | |||
|} | |||
=== 90dy-36mo === | |||
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1" | |||
|- | |||
| Age Group | |||
| Evaluation | |||
| Treatment | |||
|- | |||
| | |||
0-28d, ≥38C | |||
SBI incidence of ill appearing: 13%–21% | |||
if not ill appearing: <5% | |||
| | |||
CBC, blood Cx | |||
UA, Ucx | |||
CSF cell count, GS, Cx | |||
CXR (only if resp sx) | |||
Stool testing (if diarrhea present) | |||
| | |||
Admit | |||
Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) | |||
|- | |||
| | |||
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol) | |||
<br>SBI incidence of ill appearing: 13%–21% | |||
if not ill appearing: <5% | |||
<br> | |||
| Same as for neonates | |||
| | |||
Discharge if: | |||
1. WBC <15K but >5K and <20% bands | |||
2. UA negative | |||
Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis | Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis | ||
| Línea 60: | Línea 329: | ||
|- | |- | ||
| | | | ||
57d-6mo, ≥38 | 57d-6mo, ≥38 | ||
Non-UTI SBI incidence is estimated to be negligible | |||
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span> | |||
<br> | |||
| | | | ||
UA and Ucx alone | UA and Ucx alone | ||
OR | OR | ||
treat 57-90d using Philadelphia Protocol | treat 57-90d using Philadelphia Protocol | ||
| | | | ||
Discharge if negative | Discharge if negative | ||
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient | Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient | ||
Admit and tx with CTX if fail criteria for d/c | Admit and tx with CTX if fail criteria for d/c | ||
| Línea 84: | Línea 353: | ||
|- | |- | ||
| | | | ||
57d-6mo, ≥39 (102.2) | 57d-6mo, ≥39 (102.2) | ||
SBI incidence is estimated | SBI incidence is estimated <1%; | ||
non-UTI SBI incidence is estimated to be negligible. | non-UTI SBI incidence is estimated to be negligible. | ||
UTI is 3%–8% | UTI is 3%–8% | ||
| | | | ||
UA and Ucx alone | UA and Ucx alone | ||
OR | OR | ||
UA and Ucx + CBC + blood cx | UA and Ucx + CBC + blood cx | ||
| Línea 101: | Línea 370: | ||
| | | | ||
: | : | ||
Discharge if negative | |||
Treat for UTI as above | |||
If WBC | If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr | ||
If WBC>20K consider CXR and CSF | |||
|- | |- | ||
| | | | ||
6–36 mo | 6–36 mo | ||
Non-UTI SBI incidence is | Non-UTI SBI incidence is <0.4% | ||
UTI in girls ≤8% | UTI in girls ≤8% | ||
UTI in boys ( | UTI in boys (<12 mo) ≤ 2% | ||
Uncircumcised boys (1–2 y) remains 2% | Uncircumcised boys (1–2 y) remains 2% | ||
| | | | ||
UA and Ucx in: | UA and Ucx in: | ||
(girls 6-24mo) | (girls 6-24mo) | ||
(circ 6-12mo) | (circ 6-12mo) | ||
(uncirc 6-24mo) | (uncirc 6-24mo) | ||
| | | | ||
Discharge if negative | Discharge if negative | ||
Treat for UTI as above as outpatient | Treat for UTI as above as outpatient | ||
|- | |- | ||
| | | >36mo | ||
| No further w/u is routinely necessary | | No further w/u is routinely necessary | ||
| <br | | <br> | ||
|} | |} | ||
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d | Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d | ||
==From Tintinalli== | == From Tintinalli == | ||
{| | '''Management of patients who are well-appearing, vaccinated, and no clinical source of fever''' | ||
{| style="width: 500px" cellspacing="1" cellpadding="1" border="1" | |||
|- | |- | ||
| Age Group | | Age Group | ||
| Evaluation | | Evaluation | ||
| Treatment | | Treatment | ||
|- | |- | ||
| | | | ||
0-28d, ≥38C | 0-28d, ≥38C | ||
SBI incidence of ill appearing: 13%–21% | SBI incidence of ill appearing: 13%–21% | ||
if not ill appearing: | if not ill appearing: <5% | ||
| | | | ||
CBC, blood Cx | CBC, blood Cx | ||
UA, Ucx | UA, Ucx | ||
CSF cell count, GS, Cx | CSF cell count, GS, Cx | ||
CXR (only if resp sx) | CXR (only if resp sx) | ||
Stool testing (if diarrhea present) | Stool testing (if diarrhea present) | ||
| | | | ||
Admit | Admit | ||
Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) | Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) | ||
| Línea 177: | Línea 448: | ||
|- | |- | ||
| | | | ||
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol) | 29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol) | ||
<br | <br>SBI incidence of ill appearing: 13%–21% | ||
if not ill appearing: | if not ill appearing: <5% | ||
<br> | |||
| Same as for neonates | |||
| Same as for neonates | |||
| | | | ||
Discharge if: | Discharge if: | ||
1. WBC | 1. WBC <15K but >5K and <20% bands | ||
2. UA negative | 2. UA negative | ||
Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis | Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis | ||
| Línea 197: | Línea 468: | ||
|- | |- | ||
| | | | ||
57d-6mo, ≥38 | 57d-6mo, ≥38 | ||
Non-UTI SBI incidence is estimated to be negligible | Non-UTI SBI incidence is estimated to be negligible | ||
<span class="Apple-style-span" style="line-height: 17px">UTI is 3%–8%</span> | |||
<br> | |||
| | | | ||
UA and Ucx alone | UA and Ucx alone | ||
OR | OR | ||
treat 57-90d using Philadelphia Protocol | treat 57-90d using Philadelphia Protocol | ||
| | | | ||
Discharge if negative | Discharge if negative | ||
Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient | Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient | ||
Admit and tx with CTX if fail criteria for d/c | Admit and tx with CTX if fail criteria for d/c | ||
| Línea 221: | Línea 492: | ||
|- | |- | ||
| | | | ||
57d-6mo, ≥39 (102.2) | 57d-6mo, ≥39 (102.2) | ||
SBI incidence is estimated | SBI incidence is estimated <1%; | ||
non-UTI SBI incidence is estimated to be negligible. | non-UTI SBI incidence is estimated to be negligible. | ||
UTI is 3%–8% | UTI is 3%–8% | ||
| | | | ||
UA and Ucx alone | UA and Ucx alone | ||
OR | OR | ||
UA and Ucx + CBC + blood cx | UA and Ucx + CBC + blood cx | ||
| Línea 238: | Línea 509: | ||
| | | | ||
: | : | ||
Discharge if negative | |||
Treat for UTI as above | |||
If WBC | If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr | ||
If WBC>20K consider CXR and CSF | |||
|- | |- | ||
| | | | ||
6–36 mo | 6–36 mo | ||
Non-UTI SBI incidence is | Non-UTI SBI incidence is <0.4% | ||
UTI in girls ≤8% | UTI in girls ≤8% | ||
UTI in boys ( | UTI in boys (<12 mo) ≤ 2% | ||
Uncircumcised boys (1–2 y) remains 2% | Uncircumcised boys (1–2 y) remains 2% | ||
| | | | ||
UA and Ucx in: | UA and Ucx in: | ||
(girls 6-24mo) | (girls 6-24mo) | ||
(circ 6-12mo) | (circ 6-12mo) | ||
(uncirc 6-24mo) | (uncirc 6-24mo) | ||
| | | | ||
Discharge if negative | Discharge if negative | ||
Treat for UTI as above as outpatient | Treat for UTI as above as outpatient | ||
|- | |- | ||
| | | >36mo | ||
| No further w/u is routinely necessary | | No further w/u is routinely necessary | ||
| <br | | <br> | ||
|} | |} | ||
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d | Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d | ||
== See Also == | == See Also == | ||
*[[UTI (Peds)]] | |||
*[[Sepsis (Peds)]] | *[[UTI (Peds)]] | ||
*[[Meningitis (Peds)]] | *[[Sepsis (Peds)]] | ||
*[[Meningitis (Peds)]] | |||
*[[Febrile Seizure]] | *[[Febrile Seizure]] | ||
== Source == | == Source == | ||
Tintinalli | |||
Tintinalli | |||
[[Category:Peds]] | [[Category:Peds]] | ||
Revisión del 19:22 1 mar 2012
Harbor-UCLA Protocol
0-28dy
| Age Group | Evaluation | Treatment |
|
0-28d, ≥38C SBI incidence of ill appearing: 13%–21% if not ill appearing: <5% |
CBC, blood Cx UA, Ucx CSF cell count, GS, Cx CXR (only if resp sx) Stool testing (if diarrhea present) |
Admit Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) |
|
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
if not ill appearing: <5%
|
Same as for neonates |
Discharge if: 1. WBC <15K but >5K and <20% bands 2. UA negative Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis |
|
57d-6mo, ≥38 Non-UTI SBI incidence is estimated to be negligible UTI is 3%–8%
|
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
|
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
|
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
| >36mo | No further w/u is routinely necessary |
28dy-90dy
| Age Group | Evaluation | Treatment |
|
0-28d, ≥38C SBI incidence of ill appearing: 13%–21% if not ill appearing: <5% |
CBC, blood Cx UA, Ucx CSF cell count, GS, Cx CXR (only if resp sx) Stool testing (if diarrhea present) |
Admit Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) |
|
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
if not ill appearing: <5%
|
Same as for neonates |
Discharge if: 1. WBC <15K but >5K and <20% bands 2. UA negative Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis |
|
57d-6mo, ≥38 Non-UTI SBI incidence is estimated to be negligible UTI is 3%–8%
|
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
|
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
|
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
| >36mo | No further w/u is routinely necessary |
90dy-36mo
| Age Group | Evaluation | Treatment |
|
0-28d, ≥38C SBI incidence of ill appearing: 13%–21% if not ill appearing: <5% |
CBC, blood Cx UA, Ucx CSF cell count, GS, Cx CXR (only if resp sx) Stool testing (if diarrhea present) |
Admit Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) |
|
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
if not ill appearing: <5%
|
Same as for neonates |
Discharge if: 1. WBC <15K but >5K and <20% bands 2. UA negative Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis |
|
57d-6mo, ≥38 Non-UTI SBI incidence is estimated to be negligible UTI is 3%–8%
|
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
|
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
|
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
| >36mo | No further w/u is routinely necessary |
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
From Tintinalli
Management of patients who are well-appearing, vaccinated, and no clinical source of fever
| Age Group | Evaluation | Treatment |
|
0-28d, ≥38C SBI incidence of ill appearing: 13%–21% if not ill appearing: <5% |
CBC, blood Cx UA, Ucx CSF cell count, GS, Cx CXR (only if resp sx) Stool testing (if diarrhea present) |
Admit Ampicillin 50mg/kg + (cefotaxime 50mg/kg or gentamicin 2.5mg/kg) |
|
29-56d, ≥ 38.2 (100.8) (Philadelphia Protocol)
if not ill appearing: <5%
|
Same as for neonates |
Discharge if: 1. WBC <15K but >5K and <20% bands 2. UA negative Admit if above are not met and treat with CTX 50mg/kg if CSF normal, 100mg/kg if signs of meningitis |
|
57d-6mo, ≥38 Non-UTI SBI incidence is estimated to be negligible UTI is 3%–8%
|
UA and Ucx alone OR treat 57-90d using Philadelphia Protocol |
Discharge if negative Treat UTI w/ cefixime 8mg/kg/d or cefpodoxime 10mg/kg/d divided into BID or cefdinir 14mg/kg/d x 7-10days as outpatient Admit and tx with CTX if fail criteria for d/c |
|
57d-6mo, ≥39 (102.2) SBI incidence is estimated <1%; non-UTI SBI incidence is estimated to be negligible. UTI is 3%–8% |
UA and Ucx alone OR UA and Ucx + CBC + blood cx |
Discharge if negative Treat for UTI as above If WBC>15K consider treatment with CTX 50 mg/kg IV/IM, and follow-up in 24hr If WBC>20K consider CXR and CSF |
|
6–36 mo Non-UTI SBI incidence is <0.4% UTI in girls ≤8% UTI in boys (<12 mo) ≤ 2% Uncircumcised boys (1–2 y) remains 2% |
UA and Ucx in: (girls 6-24mo) (circ 6-12mo) (uncirc 6-24mo) |
Discharge if negative Treat for UTI as above as outpatient |
| >36mo | No further w/u is routinely necessary |
Note: Preemies - Count age by estimated postconception date (not by actual delivery date) for 1st 90d
See Also
Source
Tintinalli
